Entero Therapeutics (NASDAQ:ENTO) Trading 22.8% Higher – Time to Buy?

Entero Therapeutics, Inc. (NASDAQ:ENTO) traded up 22.8% during trading on Thursday . The stock traded as high as $2.63 and last traded at $2.48. 235,729 shares traded hands during trading, an increase of 86% from the average session volume of 126,532 shares. The stock had previously closed at $2.02.

Entero Therapeutics Stock Performance

The firm’s 50-day moving average price is $2.61 and its two-hundred day moving average price is $3.40. The stock has a market cap of $3.94 million, a price-to-earnings ratio of -1.47 and a beta of 1.19.

Hedge Funds Weigh In On Entero Therapeutics

A hedge fund recently bought a new stake in Entero Therapeutics stock. Virtu Financial LLC purchased a new stake in Entero Therapeutics, Inc. (NASDAQ:ENTO) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 11,829 shares of the company’s stock, valued at approximately $59,000. Virtu Financial LLC owned 0.74% of Entero Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 12.30% of the company’s stock.

About Entero Therapeutics

Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.

Entero’s pipeline features multiple lead candidates in varying stages of clinical development.